Press Release
Enrollment Completed
Low-Risk Aortic and Mitral Patient Groups for On-X Prosthetic Heart Valve Anticoagulation Clinical Study Low-risk aortic valve patients are maintained with aspirin and clopidogrel only AUSTIN, TX – May 7, 2013 – On-X® Life Technologies, Inc. (On-X LTI) announced today that enrollment for the Low-Risk Aortic Valve and Mitral Valve Patient Groups has been completed.…
Read MoreAATS Report: PROACT
Prospective Randomized On-X Heart Valve Clinical Trial Provides Evidence of Reduced Complications On-X aortic valve trial is the first to formally study patients maintained at levels of anticoagulation below those currently recommended by professional society guidelines, helping to lessen anticoagulation-related complications AUSTIN, TX – May 6, 2013 – On-X® Life Technologies, Inc. (On-X LTI) announced…
Read MorePredicting Long-Term Costs
Heart Valve Replacement Study to be Presented at American College of Cardiology Meeting A comparative long-term cost analysis between the On-X® Prosthetic Heart Valve and stented tissue valves shows a potential life-time savings of nearly $60,000 per patient and $1.2 billion for total U.S. healthcare AUSTIN, TX – March 8, 2013 – On-X® Life Technologies,…
Read MoreOn-X LTI Receives FDA Approval
On-X Heart Valve with Anatomic Shaped Sewing Ring The On-X Aortic Heart Valve with an anatomic shaped sewing ring matches the shape of the native aortic annulus and helps prevent flattening and distortion AUSTIN, TX – February 26, 2013 – On-X® Life Technologies, Inc. (On-X LTI) announced today that it has received approval from the…
Read MoreOn-X LTI Launches at STS 2013
CHORD-X™ ePTFE Suture for Mitral Valve Repair and Replacement Satellite Symposia Offered to Educate Surgeons on the Factors that Accelerate Tissue Valve Failure and How to Simplify Mitral Valve Repair AUSTIN, TX – January 27, 2013 – On-X® Life Technologies, Inc. (On-X LTI) announced today the availability of its newest product for heart valve repair…
Read MoreOn-X LTI Launches Innovative Heart Valve Products
European Meeting in Barcelona The On-X aortic valve with an anatomic shaped sewing ring and ePTFE suture for repair of mitral valve chordae presented at EACTS AUSTIN, TX – October 29, 2012 – On-X® Life Technologies, Inc. (On-X LTI) announced today that it is launching two new heart valve products, the On-X® Aortic Prosthetic Valve…
Read MoreOn-X Life Technologies Submits for FDA/CE Approval
Reduced Anticoagulation Indication for On-X Aortic Heart Valve If approval is received, the On-X valve will become the first aortic valve that allows patients to be maintained at levels of anticoagulation below currently recommended professional society guidelines, helping to lessen anticoagulation – related complications AUSTIN, TX – October 22, 2012 – On-X® Life Technologies, Inc.…
Read MoreOn-X Life Technologies Releases Educational Video
For Prospective Heart Valve Replacement Patients New video provides patients with information to help them make informed decisions on which type of prosthetic heart valve will best meet their long-term, quality-of-life goals AUSTIN, TX – July 25, 2012 – On-X® Life Technologies, Inc. (On-X LTI) announced today that it has produced a 14-minute Patient Education…
Read MoreThe On-X® Heart Valve Compares Favorably to Tissue Valves
Results from a study comparing the On-X mechanical heart valve to tissue valves Matched Patient Groups in Reduced Anticoagulation Trial Provide Evidence of Improved Mortality Rate for Patients AUSTIN, TX – May 23, 2012 – On-X® Life Technologies, Inc. (On-X LTI) announced today that results from a study comparing the On-X mechanical heart valve to…
Read MoreOn-X Life Technologies Releases Expected Timelines
For Reduced Anticoagulation Study Results at AATS Results for PROACT Trial provide sufficient data to permit submission of modified “Instructions for Use” to the FDA for the On-X Heart Valve for high-risk patients, as well as interim results for low-risk (aspirin and clopidogrel) patients AUSTIN, TX – April 30, 2012 – On-X® Life Technologies, Inc.…
Read More